Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Rectal Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Recurrence 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

thymoglobulin 2Thiotepa 2Stem Cell Transplantation 2Melphalan 2Ifosfamide 2Etoposide 2Bone Marrow Transplantation 2Antilymphocyte Serum 2sodium thiosulfate 1ribociclib 1omburtamab I-131 1lexatumumab 1ganitumab 1fludarabine phosphate 1copanlisib 1bempegaldesleukin 1X-Rays 1Vincristine 1Topotecan 1Temozolomide 1Tacrolimus 1Specimen Handling 1Rituximab 1Receptor Protein-Tyrosine Kinases 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1Polymerase Chain Reaction 1Platinum 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Rhabdomyosarcoma × Receptor Protein-Tyrosine Kinases × Clear all
NCT03041701 2022-04-14

Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
14 enrolled 17 charts
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡